Sections & Products

Main > > >ONCOLOGY. *

Ablation. Radio Frequency Ablation (RFA)
ElectroSurgical Device.
USA Clearance Date: 2019. 04.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.27.

Acute Radiation Syndrome. TREAT.:
Sargramostim Inj.
USA Approval Date: 2018. 06.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.07.

AntiSense DNA Therapeutics=p-Ethoxy DNA
Backbone+Liposome Technology.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.18.

BioMarker. Discovery. Reverse Proteomic
Platform. (I)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 05.12.

Biopsy. Liquid Biopsy.
Circulating Tumor Cells (CTCs.). Micro-
Filtration.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.15.

Biopsy. Liquid Biopsy.
Circulating Tumor Cells (CTCs.)+Circu-
-lating Tumor DNA (ctDNA) Technology.
Companion Diagnostics.
(*) Companies; Patents; TradeMarks &
WebSites Available on Request.
UpDate: 2018. 05.13.

Biopsy. Liquid Biopsy.
Circulating Tumor DNA (ctDNA)
Companion Diagnostics.
Only for Metastatic Solid Tumors.
(*) Company; Patent & Web-Site Availa-
ble on Request.
UpDate: 2018. 05.13.

Biopsy. Liquid Biopsy. High-Yield Sample Prep Platform
USA Launch Date: 2019. 09.20.
(*) Company; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.04.

Biopsy. Liquid Biopsy. Next Generation
Sequencing (NGS). Elimination of Recu-rrent Artifacts and Stochastic Errors
Technology.
Research Use Only.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.26.

Breast Cancer. TREAT.: DoxoRubicin.HCl
NanoParticle Vitamin A Formulation.
RU Approval Date: 2017. 08.08.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 10.01.

Cell Isolation. MicroFluidics-based
Technology.
Isolates White Blood Cells from Human Peripheral Blood.
Use: R&D & Clinical Research Labs.
Launch Date: 2019. 12.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.02.

Cell Therapy. DLD Microfluidic-Chip Ba-
sed Technology.
CAR-T Therapy.
DLD: Deterministic Lateral Displacement.
Leukapheresis.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 06.18.

ChemoTherapy. Anemia. Treat.: Epoetin Alfa. (U)
Approval Date: ?
ReCombinant Erythropoietin
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy. Anemia. Treat.: Epoetin Beta. (C)
ReCombinant Erythropoietin.
Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.18.

ChemoTherapy. Anemia. Treat.: Darb- Epoietin-Alfa Inj.
Non-Myeloid Cancers.
ReCombinant Long Lasting Erythropoitin.
Sialylated Erythropoietin.
USA Approval Date: ?
(*) Company : Amgen.
Patent : Expired
TradeMark: Aranesp
Web-Site : www.aranesp.com/
UpDate: 2018. 09.21.

ChemoTherapy. AnthraCycline ExtraVasa-
tion. AntiDote: Dexrazoxane.HCl for Inj.
USA Approval Date: 2017. 07.10.
USA Launch Date : 2017. 09.25.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.21.

ChemoTherapy. Hair Loss Prevention:
Scalp Cooling.
(*) Company; Patent & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.21.

ChemoTherapy. Induced Nausea & Vomiting
Treat.: Aprepitant Capsules; for Oral
Suspension. (U)
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy. Induced Nausea & Vomiting
Treat.: Aprepitant Inj. Emulsion. (U)
USA Approval Date: 2017. 11.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy. Induced Nausea & Vomiting
Treat.: Cannabinoid Dronabinol Oral Solution CII.
Version of TetraHydroCannabinol.
USA Approval Date: 2016. 07.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy. Induced Nausea & Vomiting
Treat.: Extended Release Granisetron Inj. (U)
USA Approval Date: 2016. 08.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy. Induced Nausea & Vomoting
Treat.: Granisetron Inj.
(*) Company : Roche
Patent : Expired 2007. 12.29.
TradeMark: Kytril
UpDate: 2018. 09.18.

ChemoTherapy. Induced Nausea & Vomiting.
Treat.: Granisetron TransDermal System.
(J)
USA Approval Date: 2008. 09.12.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.18.

ChemoTherapy. Induced Nausea & Vomiting.
Treat.: Netupitant+Palonosetron Cap. (C)
EU Approval Date: 2015. 05.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.18.

ChemoTherapy. Induced Nausea & Vomi-
ting. Treat.: Palonosetron.HCl Inj. (C)
EU Approval Date : 2015. 05.27.
USA Approval Date: 2003. 07.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.18.

ChemoTherapy. Induced Nausea & Vomi-
ting. Treat.: Palonosetron.HCl Inj. (I)
Generics.
USA Launch Date: 2018. 03.23.
(*) Company Available on Request.
UpDate: 2018. 09.18.

ChemoTherapy. Induced Nausea & Vomi-
ting. Treat.: Palonosetron.HCl Inj. (K)
(*) Company; Patent & Web-Site Availa-
ble on Request.
UpDate: 2018. 09.21.

ChemoTherapy. Induced Nausea & Vomi-
ting. Treat.: Rolapitant.
- IV Form:
USA Approval Date: 2017. 10.25
USA Launch Date : 2017. 11.28
- Tablet Form:
EU Approval Date : 2017. 04.26
USA Approval Date: 2015. 09.01
NeuroKinin-1 Receptor AntAgonist
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy. Neutropenia. Treat.:
Filgrastim. BioSimilar. (C)
USA Launch Date: 2015. 07.22.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.18.

ChemoTherapy. Neutropenia. Treat.:
Filgrastim. BioSimilar. (S)
(*) Company : SciGen Ltd.
TradeMark: SciLocyte
UpDate: 2018. 09.21.

ChemoTherapy>Neutropenia. Treat.:
Filgrastim Brand. (U)
Approved
Mechanism: GCSF
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy>Neutropenia. Treat.: PegFilgrastim. Brand.
Long Acting Version of Filgrastim
USA Approval Date: 2002. 01.31.
(*) Company : Amgen
Patents : Expired
TradeMark: Neulasta
Web-Site : www.neulasta.com
UpDate: 2018. 09.23.

ChemoTherapy. Neutropenia. Treat.: Sargramostim.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy. Peptide. Thymosin Alpha 1,
TA1; Thymalfasin
USA Approval Date: ?
Utility>Decrease in Side Effects
>Increase in Effectiveness
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.

ChemoTherapy. Sensitivity Assay.
(*) Company : Pieran Holdings Inc.
TradeMark: ChemoINTEL
Web-Site :
pierianbio.com/project/chemo-intel/
UpDate: 2018. 09.23.

Clinical Trial Patient Matching. 2.0 NGS Test.
For Patients: No Cost
Pharma. Co. Customers: Clovis Oncology.
Epizyme
Precision Oncology.
USA Launch Date: 2017. 05.23.
(*) Company : Strata Oncology
Web-Site : www.strataoncology.com
UpDate: 2018. 09.23.

Colon Cancer. Diagnostics. Balloon Endoscope.
Approved in EU & IL.
Practiced at IL Hospital ..
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.

Colon Cancer. Diagnostics. Capsule-Ba-
sed System.
Preparation-Free.
Utilizing Ultra-Low Dose X-Ray &
Wireless Communication Technologies ..
EU Approval Date: 2018. 01.10.
IL Approval Date: 2018. 09.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.24.

Colon Cancer. Diagnostics. Colonoscopy.
Cleansing. Na PicoSulfate+MgO+Anhydrous+
Citric Acid Ready-to-Drink Low-Volume
Premixed Liquid Solution.
USA 2nd Approval : 2017. 11.29.
USA Initial Approval: 2012.
USA Launch Date : 2018. 02.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.

Colon Cancer. Diagnostics. Colonoscopy.
Cleansing. Na2SO4/K2SO4/MgSO4 Oral Solution. Brand.
USA Approval Date: 2010. 08.05.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 09.25.

Colon Cancer. Diagnostics. Colonoscopy.
Cleansing. Na2SO4/K2SO4/MgSO4 Oral Solution. Generics.
USA Approval Date: 2016. 08.23.
(*) Company: Perrigo.
UpDate: 2018. 09.24.

Colon Cancer. Diagnostics. Colonoscopy.
Cleansing. PEG 3350+Na Ascorbate+Na2SO4+
Ascorbic Acid+NaCl+KCl Powder for Oral
Solution.
USA Approval Date: 2018. 05.07.
USA Launch Date : 2018. 09.11.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.

Colon Cancer. Diagnostics. Colonoscopy.
Cleansing. Pulsed Irrigation Air+H2O
Device.
Used during Procedure in case of InCom-
plete Pre-Procedure Cleaning.
EU Approval Date : 2018. 02.27.
USA Approval Date: 2016. 09.26.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 09.24.

Colon Cancer. Diagnostics. Colonoscopy.
Surgery. Polyp Removal.
EU Approval Date : 2016. 03.10.
USA Approval Date: 2017. 05.03.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 09.25.

Colon Cancer. Diagnostics. Computed
Tomography (CT) Colonography (Virtual Colonoscopy)>Computer Aided Detection (CAD) (I)
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.25.

Colon Cancer. Diagnostics. Computed
Tomography (CT) Colonography (Virtual Colonoscopy)>Computer Aided Detection (CAD) (U)
Polyp Detection.
Launched in CA; EU & USA.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.

Colon Cancer. Diagnostics. Disposable
Colonoscope. (D)
EU Approval Date : 2018. 03.20.
USA Approval Date: 2018. 01.09.
(*) Company : Ambu AS.
Web-Site : www.ambu.com
UpDate: 2018. 09.24.

Colon Cancer. Diagnostics. Disposable
Colonoscope. (I)
Features>CMOS Camera
>Miniaturized
>No Sedation Required
>Self Navigating
>Self Propelling
Optical Colonoscopy Risk.
USA Clearance Date: 2014. 12.03.
USA Clearance Date: 2016. 09.20+
+Therapeutic Intervention.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.24.

Colon Cancer. Diagnostics. DNA Septin9 Blood Test.
AR Approval Date : 2014. 03.10.
CN Approval Date : 2014. 12.08.
EU Launch Date : 2011. 10.25.
USA Approval Date: 2016. 04.13.
USA Launch Date : 2016. 04.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.24.

Colon Cancer. Diagnostics. Genomic Stool Test.
USA Approval Date: 2014. 08.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.

Colon Cancer. Diagnostics. Nucleosome Blood Test.
EU Approval Date: 2016. 12.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.

Colon Cancer. Prognostics. CTCs Detecting Test. (Metastatic).
Patent>Expiration Date: 2019. 02.12.
USA>Approval Date: 2006. 12.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.27.

Colon Cancer. Prognostics. Gene BioMar- kers Blood Test.
CA>Ontario Launch Date: ?
USA Approval Date : 2012. 02.21.
USA Launch Date : 2012. 04.10.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.26.

Colon Cancer. Prognostics. Software.
Approved in EU & IL
- Description:
Software Analyzes EMRs. Particularly
"Total Blood Counts" for "Low Hemoglo
bin" trends
NO Patient Involvement
NO Blood Test
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.26.

Colon Cancer. Recurrence. Hyper Me BCAT1 & IKZF1 Genes PCR-Based Blood Test.
USA Launch Date: 2016. 12.20.
Blood ccfDNA Collection Tube>
>Collected in a Physicians Office.
>Implementation Date: 2017. 08.21.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2019. 10.24.

Colon Cancer. Recurrence. Risk Immune
Response Scoring In-Vitro Diagnostic
Test.
(Early Stage/Localized Colon Cancer).
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.10.

Colon Cancer. Recurrence. Stage II/III A/B Multi Gene Test.
WorldWide Avalaibility.
(*) Company : Genomic Health
TradeMark: OncoType DX.
Web-Site :
/www.genomichealth.com/en-US
UpDate: 2018. 09.26.

Colon Cancer. TREAT.: BevacizuMAb.
Brand. (METASTATIC)
Mechanism> VEGF Inhibition.
USA Approval Date: 2004. 02.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.27.

Colon Cancer. TREAT.: CetuxiMAb (METAS-
TATIC; KRAS+).
>Companion Diagnostics>
Company : BioCept Inc.
Liquid Biopsy (Blood Test)
USA Launch Date: 2015. 08.05
USA Approval Date: 2009. 07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.28.

Colon Cancer. TREAT.: Regorafenib (METAS
TATIC)
Oral Multi-Kinase Inhibition.
CN, EU & JP Approval Date: ?
USA Approval Date: 2012. 09.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.27.

Colon Cancer. TREAT.: Trifluridine +Tipiracil Tablets. (METASTATIC)
EU Approval Date : 2016. 04.28.
JP Approval Date : ?
USA Approval Date: 2015. 09.22.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.27.

Companion Diag. Solid Tumors.
BioMarker Platform.
Inform a CT (Non)Effectiveness?
>Measures Phosphorylated Proteins>
in tumor tissue. Phosphorylated
proteins represent active targets for
drugs
>Uses RPPA Technology>
to measure the quantity, activity and
downstream signaling pathway activation
levels for receptors of FDA-approved
and investigational drugs in order to
determine whether or not a prescribed
medication is likely to be effective in
treating the cancer of a specific
patient at that moment in time.
This highly sensitive analysis empowers
physicians to make better treatment
decisions by giving a greater degree of
certainty as to whether a specific drug
will work in treating a specific
patient, as well as informing a
physician whether a chemotherapy
treatment is unlikely to be effective.
This information potentially allows the
patient to forego the devastating side
effects of cytotoxic treatments that
are unlikely to deliver clinically
meaningful benefit, while guiding
physicians to prescribing treatments
likely to yield maximum benefit.
RPPA: Reverse Phase Protein Array.
Tumor Types: Breast; Colon; Pancreatic.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.29.

Companion Diag. Solid Tumors.
Drug Response Predictor. mRNA-Based.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 09.29.

Companion Diag. Solid Tumors.
Genomic Profiling Test.
USA Approval Date: 2017. 11.30.
USA Launch Date : 2018. 03.30.
(*) Company : Foundation Medicine.
TradeMark: FoundationOne CDx
UpDate: 2018. 09.29.

Companion Diag. Solid Tumors.
Overall Tumor Mutation Burden (TMB)
Platform>Whole Exome Sequencing.
USA Approval Date: 2019. 11.12.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.03.

Diag.>Imaging. Single Photon Emission
Computerized Tomography (SPECT). Radio-
Pharma: Technetium Tc 99m Tilmanocept
Injection.
USA Approval Date: 2013.05.01.>
>Guiding Sentinel Lymph Node in Patients
with Breast Cancer; Melanoma
USA Approval Date: 2014.06.13.>
>Guiding Sentinel Lymph Node in Patients
with squamous cell carcinoma of the
oral cavity in head and neck region.
USA Approval Date: 2014.10.>
>lymphatic mapping agent for solid
tumors where it is a component of the
intraoperative MAN./Procedure/
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.22.

Diag.>Imaging. Surface-Enhanced Raman spectroscopy (SERS) Technology.
(*) Company : Fujifilm.
PR Web-Site:
www.fujifilm.com/news/n180419.html
UpDate: 2018. 06.17.

Diag.>Pathology Software.
EU Approval Date: 2019. 11.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.03.

Diag.>Positron emission tomography (PET)
Platform.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.26.

Drug Delivery. Focused Resonance Nano-Permeabilization (FORN) Device.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.28.

Drug Delivery. Polymer NanoParticles
Platform.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.01.

Drug Delivery. TriFunctional Polypeptide
Technology.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.01.

Drug Discovery. Decoy Oligo Nucleotides
Chemistry Platform.
Introduction Date: 2017. 10.02.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.01.

Drug Discovery. Kinase Inhibition Plat-
form.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.22.

Exosomes. Extracorporeal Removal Device.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.26.

Eye Cancer. Uveal Melanoma. Prognostics.
Metastasis To Liver. NGS Panel.
Launch Date: 2018. 01.08.
UpDate: 2018. 10.01.

Gene Delivery. LentiViral Technology.
(*) Company : Oxford BioMedica PLC.
TradeMark: LentiVector
Web-Site :
www.oxfordbiomedica.co.uk/technology
UpDate: 2018. 10.02.

Gene Mutation. Detection Kits.
Launch Date: 2018. 10.29.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.12.

Genomics>Genetic Tests. Artificial Intelligence (AI) & Machine Learning IDentification (ID) Platform.
USA Launch Date: 2019. 05.21.
(*) Company; USA Patent APP.; TradeMark
& Web-Site Available on Request.
UpDate: 2019. 12.09.

Genomics>Targeted Locus Amplification (TLA) for Complete Cancer Gene Mutation Sequencing.
Launch Date: 2019. 12.12.
(*) Company; Patent APPs.; & Web-Site
Available on Request.
UpDate: 2019. 12.26.

ImmunoTherapy. 3 Naked mRNA>0>1>2>3.
>0 Technology
>1 caTLR4>
that activates the immune system as it
evokes dendritic cells to present
antigens to the CD4/CD8 T-cells
>2 CD40L>
that induces the dendritic cells to
initiate the antigen-specific action of
the CD4 T-cells
3 CD70>
that induces the dendritic cells to
initiate the immune system of the CD8
T-cells
Dendritic Cell Pathway.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.02.

ImmunoTherapy. AntiBody (AB) Linker-Masking Peptide Platform.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.03.

ImmunoTherapy. Bacteria>Listeria>Mono-
cytogenes>Antigen Delivery Platform.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.03.

ImmunoTherapy. Dendritic Cells Techno-
logy.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.03.

ImmunoTherapy. Human AntiBody (AB) Libra
ry.
>60 Billion Unique AB. Fragments>
(also termed �scFv�). From this
antibody library, drug candidates
directed to any target molecule can be
developed. The design of the library
enables the development of highly
functional antibodies.
The individual antibody fragments in
have distinct specific sequences in the
six so-called hypervariable regions
which constitute the antibody surface
that binds to the target molecules. The
rest of the scFv sequence is identical
in all antibodies in the library and
was selected to achieve optimal
properties in regard to e.g. stability
and manufacturability. The variability
in .. is designed to mimic and exceed
the variability in natural human
antibodies.
>Technology Platform.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.03.

ImmunoTherapy. Human AntiBody (AB) Opti-
mization>Molecular Evolution Technology
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.03.

ImmunoTherapy. Human BiSpecific AB (Anti
Body) Technology.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.02.

ImmunoTherapy. NeoAntigens Peptides.
(*) Company; Patent & Web-Site Availa-
ble on Request.
UpDate: 2018. 10.03.

ImmunoTherapy. Tri-Specific T Cell
Activating Construct Technology.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.03.

Information Web-Site. www.cancer.net

Minimal Residual Disease (MRD) & Recu-
rrence Monitoring. Circulating Tumor DNA
Assay for Patients Previously Diagnosed
with Cancer.
EU CE Mark Date: 2020. 08.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 10.01.

NanoTechnology. Au PEG-Thiol Platform.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.21.

NanoTechnology. NIR (Near InfraRed) Dye-Rigid SiO2 Shell-PEG (PolyEthylene Gly-
col) NanoParticles Platform.
DIAG. & TREAT. Primary Solid Tumor &
Metastatic Cancers
(*) Company; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 08.15.

NanoTechnology. SuperCritical Precipita-
tion+Spray Drying Platform.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 11.21.

Platelet. Transfusion. Quality Non-Inva-
sive 5-Minute Optical Test based on
Dynamic Light Scattering.
High Quality Linked to "NON-ACTIVATED"
Platelets i.e. LOW CONTENT OF MICROPAR-
TICLES.
Blood/Hematology Cancers>
>Leukemia
>Lynphoma
>Multiple Myeloma.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.30.

Polycythaemia Vera. Treat.: Ropeginter- feron alfa-2b.
EU CE Mark Date : 2019. 02.20.
TW Approval Date: ?
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.09.

Protein. Targeted Degradation Platform.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.02.

Radiomics. AI-Enabled Precision Imaging
& Segmentation.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.15.

RadioTherapy>Adaptive Therapy+Artificial
Intelligence (AI).
USA FDA 510(k) Clearance: 2020. 02.11.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.15.

RadioTherapy>BrachyTherapy>Patient
Transport System.
Release Date: 2018. 07.17.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.18.

RadioTherapy>Magnetic Resonance (MR)/
RadioTherapy (RT) Technology.
CA Approval Date : 2019. 03.25.
EU Approval Date : 2018. 06.18.
JP Approval Date : 2019. 05.24.
USA Approval Date: 2018. 12.05.
USA Approval Date: 2019. 12.16.>
>Diffusion-Weighted Images (DWI) to
include biologic assessment of "tumor
response during therapy".
DWI creates a map of the diffusion of
"water" molecules at the cellular level
and can be processed to generate the
apparent diffusion coefficient, or ADC.
A growing body of evidence shows that
ADC changes within a tumor can provide
important insights into an individual s
tumor response that would previously
have been unavailable during radiation
treatment.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.26.

RadioTherapy>Marking/Reference Points.
Permanent Make-Up (PMU)-Like Technology.
(*) Company; Patent & Web-Site Availa-
ble on Request.
UpDate: 2019. 12.30.

RadioTherapy>Robotic IntraOperative Radiation Therapy (IORT) System.
Eliminates Weeks of Post-Surgery RT.
Single RT at Point of Surgery.
USA Clearance Date: 2019. 02.26.
(*) Company; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.12.

RadioTherapy>Temporary RadioTherapy (RT) Vault.
(*) Company; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.12.

RNA (Ribo Nucleic Acid)-Based Solid Tu-mor Profiling Kit.
Developed for laboratories wishing to derive the immune composition of tumor samples.
For Use in Clinical Sequencing Laborato-
ries.
The tumor s immune composition is pro- ving to be a valuable indicator of response to current immunotherapies and the numerous drugs in development.
Launch Date: 2018. 10.30.
(*) Company : CoFactor Genomics Inc.
TradeMark: ImmunoPrism
Web-Site :
cofactorgenomics.com/immunoprism-
assay/
UpDate: 2018. 11.12.

Skin Cancer. Melanoma. Diagnostics.
Pigmented Lesion Assay.
CA Approval Date: 2018. 01.04.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.29.

Software. Cancer Care Insights & Analy- tics.
USA Launch Date: 2019. 06.18.
(*) Company; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.05.

Solid Tumors. Infusion System. Solution Designed to Overcome Infusion Barriers within Solid Tumors including Hepato Cellular Carcinoma (HCC) and Liver Metastases.
Engineered for Improved Selectivity in Complex Vasculature.
USA Launch Date: 2020. 01.13.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.14.

Staging. Tissue Dissection Instrument.
Deliver all Lymph Nodes for Complete Review.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2021. 02.20.

Surgery. Orthopaedics Surgery. Persona-
lized Virtual Surgical Planning.
USA Launch Date: 2019. 09.26.
(*) Company : Onkos Surgical Inc.
TradeMark: My3D
Web-Site :
onkossurgical.com/my3d-technologies/
UpDate: 2020. 01.05.

Surgery. Trays. Personalized Instrument Trays
USA Launch Date: 2019. 02.07.
(*) Company : Onkos Surgical Inc.
TradeMark: MyTray
Web-Site :
onkossurgical.com/products/mytray/
UpDate: 2020. 01.05.

Tissue Degeneration. RFQMR Platform QMRT
EU CE Mark Since 2012.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.28.

Tumor MicroEnvironment. 3D Tumor Model
Platform.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2021. 02.15.

Tumor MicroEnvironment. Multiplexed Ti-
ssue Analysis.
to Empower Pharmaceutical Discovery &
& Development Programs.
The Device can simultaneously image forty or more individual proteins on a single slide with the reproducibility needed for large clinical studies.
For Research Use Only.
Research Services Offering: 2020. 02.11.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 02.15.

>ONCOLOGY. *'s products
This section has no products